Next Article in Journal
CAMO 2020 Annual Meeting Abstracts
Previous Article in Journal
Association between Known Risk Factors and Colorectal Cancer Risk in Indigenous People Participating in the Ontario Familial Colon Cancer Registry
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Multidisciplinary Management of Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma

1
Centre hospitalier universitaire de Québec–Université Laval, Quebec City, QC, Canada
2
Western University, London, ON, Canada
3
Departments of Surgery and of Pathology, Dalhousie University, Halifax, NS, Canada
4
University of Toronto, Toronto, ON, Canada
5
Women’s College Hospital, Toronto, ON, Canada
6
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(4), 399-407; https://doi.org/10.3747/co.27.6015
Submission received: 4 May 2020 / Revised: 10 June 2020 / Accepted: 6 July 2020 / Published: 1 August 2020

Abstract

Non-melanoma skin cancers are the most prevalent form of cancer, with cutaneous squamous cell carcinoma (cSCC) being the 2nd most common type. Patients presenting with high-risk lesions associated with locally advanced or metastatic cSCC face high rates of recurrence and mortality. Accurate staging and risk stratification for patients can be challenging because no system is universally accepted, and no Canadian guidelines currently exist. Patients with advanced cSCC are often deemed ineligible for either or both of curative surgery and radiation therapy (RT) and, until recently, were limited to off-label systemic cisplatin–fluorouracil or cetuximab therapy, which offers modest clinical benefits and potentially severe toxicity. A new systemic therapy, cemiplimab, has been approved for the treatment of locally advanced and metastatic cSCC. In the present review, we provide recommendations for patient classification and staging based on current guidelines, direction for determining patient eligibility for surgery and RT, and an overview of the available systemic treatment options for advanced cSCC and of the benefits of a multidisciplinary approach to patient management.
Keywords: cutaneous squamous cell carcinoma; locally advanced disease; metastatic disease; staging; stratification; multidisciplinary management cutaneous squamous cell carcinoma; locally advanced disease; metastatic disease; staging; stratification; multidisciplinary management

Share and Cite

MDPI and ACS Style

Claveau, J.; Archambault, J.; Ernst, D.S.; Giacomantonio, C.; Limacher, J.J.; Murray, C.; Parent, F.; Zloty, D. Multidisciplinary Management of Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma. Curr. Oncol. 2020, 27, 399-407. https://doi.org/10.3747/co.27.6015

AMA Style

Claveau J, Archambault J, Ernst DS, Giacomantonio C, Limacher JJ, Murray C, Parent F, Zloty D. Multidisciplinary Management of Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma. Current Oncology. 2020; 27(4):399-407. https://doi.org/10.3747/co.27.6015

Chicago/Turabian Style

Claveau, J., J. Archambault, D.S. Ernst, C. Giacomantonio, J.J. Limacher, C. Murray, F. Parent, and D. Zloty. 2020. "Multidisciplinary Management of Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma" Current Oncology 27, no. 4: 399-407. https://doi.org/10.3747/co.27.6015

APA Style

Claveau, J., Archambault, J., Ernst, D. S., Giacomantonio, C., Limacher, J. J., Murray, C., Parent, F., & Zloty, D. (2020). Multidisciplinary Management of Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma. Current Oncology, 27(4), 399-407. https://doi.org/10.3747/co.27.6015

Article Metrics

Back to TopTop